112 related articles for article (PubMed ID: 7216589)
1. Is dapsone safe?
Pettit JH
Int J Dermatol; 1981 Mar; 20(2):106-7. PubMed ID: 7216589
[No Abstract] [Full Text] [Related]
2. Haemolytic effects of DDS in leprosy patients.
Khaire DS; Magar NG
Indian J Med Res; 1972 Oct; 60(10):1510-9. PubMed ID: 4661662
[No Abstract] [Full Text] [Related]
3. The antimalarial and hemolytic properties of 4,4-diaminodiphenyl sulfone (DDS).
Powell RD; DeGowin RL; Eppes RB; McNamara JV; Carson PE
Int J Lepr Other Mycobact Dis; 1967; 35(4):590-604. PubMed ID: 4869693
[No Abstract] [Full Text] [Related]
4. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.
Luzzatto L
Lancet; 2010 Aug; 376(9742):739-41. PubMed ID: 20599264
[No Abstract] [Full Text] [Related]
5. Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity.
Ranawaka RR; Mendis S; Weerakoon HS
Lepr Rev; 2008 Dec; 79(4):436-40. PubMed ID: 19274991
[TBL] [Abstract][Full Text] [Related]
6. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy.
Todd P; Samaratunga IR; Pembroke A
Clin Exp Dermatol; 1994 May; 19(3):217-8. PubMed ID: 8033379
[TBL] [Abstract][Full Text] [Related]
7. Dapsone-Associated Hemolytic Anemia in Renal Transplant Recipients With Normal Glucose-6-Phosphate-Dehydrogenase Levels.
Khatri A; Lal M R S; Bhaskaran MC
Am J Ther; 2022 May-Jun 01; 29(3):e369-e372. PubMed ID: 32947344
[No Abstract] [Full Text] [Related]
8. Treatment of leprosy.
Kulkarni AG
Natl Med J India; 1992; 5(2):96. PubMed ID: 1304277
[No Abstract] [Full Text] [Related]
9. Glucose-6-phosphate dehydrogenase deficiency and intravascular haemolysis.
Onadeko BO; Bademosi O
Ir J Med Sci; 1974 Jul; 143(4):208-13. PubMed ID: 4852166
[No Abstract] [Full Text] [Related]
10. Effect of dapsone on haemoglobin concentration in patients with leprosy.
Byrd SR; Gelber RH
Lepr Rev; 1991 Jun; 62(2):171-8. PubMed ID: 1870379
[TBL] [Abstract][Full Text] [Related]
11. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
12. Sulfonamides and sulfones in dermatologic therapy.
Bernstein JE; Lorincz AL
Int J Dermatol; 1981 Mar; 20(2):81-8. PubMed ID: 7012050
[No Abstract] [Full Text] [Related]
13. Dapsone haemolysis in leprosy. A preliminary report.
Menezes S; Rege VL; Sehgal VN
Lepr India; 1981 Jan; 53(1):63-9. PubMed ID: 7218764
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency.
Mysore V; al-Suwaid AR
Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):159-61. PubMed ID: 10472369
[No Abstract] [Full Text] [Related]
15. Chemotherapy in Leprosy.
Leiker DL
Int J Dermatol; 1975 May; 14(4):254-62. PubMed ID: 1093982
[No Abstract] [Full Text] [Related]
16. Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity.
Figueiredo MS; Pinto BO; Zago MA
Acta Haematol; 1989; 82(3):144-5. PubMed ID: 2510435
[TBL] [Abstract][Full Text] [Related]
17. Neonatal haemolytic disease due to dapsone.
Hocking DR
Med J Aust; 1968 Jun; 1(26):1130-1. PubMed ID: 4969972
[No Abstract] [Full Text] [Related]
18. Incidence of anemia in leprosy patients treated with dapsone.
Puavilai S; Chutha S; Polnikorn N; Timpatanapong P; Tasanapradit P; Charuwichitratana S; Boonthanom A; Wongwaisayawan H
J Med Assoc Thai; 1984 Jul; 67(7):404-7. PubMed ID: 6512448
[No Abstract] [Full Text] [Related]
19. Acne fulminans with dapsone induced haemolysis: a case report.
Ismail R
Med J Malaysia; 1987 Jun; 42(2):124-6. PubMed ID: 2971861
[No Abstract] [Full Text] [Related]
20. High dose dapsone toxicity.
Shelley WB; Goldwein MI
Br J Dermatol; 1976 Jul; 95(1):79-82. PubMed ID: 952745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
